About CTI BioPharma Corp.
CTI BioPharma Corp. (CTI) is a biopharmaceutical company focused on the acquisition, development and commercialization of targeted therapies covering a spectrum of blood-related cancers to patients and healthcare providers. The Company is primarily focused on commercializing PIXUVRI in select countries in the European Union, for multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (NHL). It is also engaged in evaluating pacritinib for the treatment of adult patients with myelofibrosis. Its earlier stage product candidate, tosedostat, is an oral, once-daily aminopeptidase inhibitor that has demonstrated responses in patients with acute myeloid leukemia (AML). It also evaluates its pipeline candidate paclitaxel poliglumex (Opaxio), which targets solid tumors. It is evaluating Opaxio through cooperative group sponsored trials and investigator-sponsored trials (ISTs), such as the ongoing maintenance therapy trial in patients with ovarian cancer.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology
- Sub-Industry: N/A
- Exchange: NASDAQ
- Symbol: CTIC
- Previous Close: $4.27
- 50 Day Moving Average: $4.89
- 200 Day Moving Average: $1.59
- 52-Week Range: $28,001,000.00 - $0.31
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -1.58
- P/E Growth: 0.00
- Market Cap: $119.56M
- Outstanding Shares: 28,001,000
- Beta: 0.96
- Net Margins: -119.60%
- Return on Equity: -188.29%
- Return on Assets: -64.52%
Companies Related to CTI BioPharma Corp.:
- Debt-to-Equity Ratio: 1.07%
- Current Ratio: 1.47%
- Quick Ratio: 1.41%
What is CTI BioPharma Corp.'s stock symbol?
CTI BioPharma Corp. trades on the NASDAQ under the ticker symbol "CTIC."
When did CTI BioPharma Corp.'s stock split? How did CTI BioPharma Corp.'s stock split work?
CTI BioPharma Corp. shares reverse split on Tuesday, January 3rd 2017. The 1-10 reverse split was announced on Friday, December 9th 2016. The number of shares owned by shareholders was adjusted after the closing bell on Friday, December 30th 2016. An investor that had 100 shares of CTI BioPharma Corp. stock prior to the reverse split would have 10 shares after the split.
Where is CTI BioPharma Corp.'s stock going? Where will CTI BioPharma Corp.'s stock price be in 2017?
1 analysts have issued 1 year price targets for CTI BioPharma Corp.'s shares. Their predictions range from $7.50 to $7.50. On average, they anticipate CTI BioPharma Corp.'s stock price to reach $7.50 in the next year.
When will CTI BioPharma Corp. announce their earnings?
CTI BioPharma Corp. is scheduled to release their next quarterly earnings announcement on Thursday, March, 2nd 2017.
Who owns CTI BioPharma Corp. stock?
CTI BioPharma Corp.'s stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Stonepine Capital Management LLC (9.35%), Renaissance Technologies LLC (6.22%), FMR LLC (3.40%), United Capital Financial Advisers LLC (1.88%) and Commerzbank Aktiengesellschaft FI (1.27%). Company insiders that own CTI BioPharma Corp. stock include Jack W Singer, James A Bianco, Louis A Bianco, Matthew Plunkett, Richard L Love and Value Fund L P Biotechnology.
Who sold CTI BioPharma Corp. stock? Who is selling CTI BioPharma Corp. stock?
CTI BioPharma Corp.'s stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Renaissance Technologies LLC and Commerzbank Aktiengesellschaft FI. Company insiders that have sold CTI BioPharma Corp. stock in the last year include James A Bianco and Matthew Plunkett.
Who bought CTI BioPharma Corp. stock? Who is buying CTI BioPharma Corp. stock?
CTI BioPharma Corp.'s stock was bought by a variety of institutional investors in the last quarter, including Stonepine Capital Management LLC.
How do I buy CTI BioPharma Corp. stock?
Shares of CTI BioPharma Corp. can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of CTI BioPharma Corp. stock cost?
One share of CTI BioPharma Corp. stock can currently be purchased for approximately $4.27.